Understanding and treating severe side effects of CAR T-cell therapy
Official title: Calming the Cytokine Storm: Unraveling the Biology of CRS and ICANS
Funded at Children's Hosp of Philadelphia · NIH-10783934 · Data updated 2026-11-12
This study is looking at the serious side effects that some people experience after CAR T-cell therapy, like fever and confusion, to find out what causes them, so we can create better treatments that make this therapy safer for patients with leukemia.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hosp of Philadelphia NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $248,509 |
| NIH project number | 1K08CA286762-01 |
| Project ID | NIH-10783934 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients undergoing CAR T-cell therapy for acute B-lymphoblastic leukemia who may experience severe side effects.
✕Less likely to help
Patients who are not receiving CAR T-cell therapy or those with other types of cancer unrelated to the study may not benefit from this research.
What this research studies
This research focuses on the severe side effects that can occur with CAR T-cell therapy, specifically Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS). The researchers aim to identify the cellular and molecular triggers of these conditions using advanced techniques like single cell RNA sequencing. By understanding how the immune system contributes to these toxicities, the study seeks to develop new therapies to prevent and treat them effectively. This could lead to safer CAR T-cell treatments for patients with certain types of leukemia.
Why it matters
Potential benefit: If successful, this research could lead to improved safety and effectiveness of CAR T-cell therapies for patients with leukemia.
How similar studies have gone: Previous research has shown promise in understanding and managing CRS, but the approach to ICANS is still largely untested.
Where this research is happening
-
Children's Hosp of Philadelphia
Philadelphia, United States Active
Researchers
- Principal investigator: Diorio, Caroline — Children's Hosp of Philadelphia
- Study coordinator: Diorio, Caroline
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.